2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non–small cell lung cancer.
Leora Horn, MD, MSc, FRCPC, associate professor of cancer research, Vanderbilt Ingram Cancer Center, associate professor of medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, discusses the role of mobocertinib (TAK-788) in patients with non–small cell lung cancer (NSCLC).
Mobocertinib is an EGFR TKI that is developed for the treatment of patients with EGFR exon 20–mutant and HER2-mutant NSCLC, says Horn.
Notably, minimal data are available with regard to patients with exon 20 insertions because it is a rare mutation that, historically, has not been responsive to first- or second-generation EGFR TKIs, Horn explains.
However, data compiled from Flatiron Health proved beneficial in terms of comparing the responses of patients with exon 20 mutations who received traditional therapies with those who received mobocertinib on the phase 1/2 study (NCT02716116), Horn concludes.